Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Highlights from AGN’s 1Q11 CC:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 476
Posts 80,630
Boards Moderated 23
Alias Born 09/05/02
160x600 placeholder
Why September May Slow Further S&P Records
September has recently started shedding its reputation as one of the worst stock market months of the year, but strategists note the psychological pressure of big round numbers in the S&P 500 Index and the looming end of Federal Reserve asset purchases may serve to reinforce the month's stereotype.
Top Equities Stories Of The Day
Apple Investigating Reports of iCloud Vulnerabilities
US Court Dismisses Aluminum Antitrust Cases
J.P. Morgan Working With Law Enforcement on Cyber Attack -- 3rd Update
U.S. Hot Stocks: Hot Stocks to Watch
Australia's RBA Holds Interest Rates Steady
U.S. Hot Stocks: Hot Stocks to Watch
Ex-LPL Broker Ordered to Pay Nearly $2 Million
Ukraine Tensions Spur U.S. Stock Futures Downward
DewDiligence Member Level  Wednesday, 05/04/11 03:11:09 PM
Re: DewDiligence post# 114167
Post # of 181585 
Highlights from AGN’s 1Q11 CC:

• 2011 non-GAAP EPS guidance raised by $0.02 to a range $3.56-3.62 (+14% YoY).

• Botox: $365M, +9% YoY in local currencies. Dysport, the main competitor, remains stuck at a 17% procedure share in US cosmetic indications and a de minimis share in US medical indications share (#msg-62706265, #msg-49695053). Xeomin’s US market share in also de minimis. Worldwide in all indications, Botox has an 80% market share.

• Juvederm franchise: $88M, +47% YoY in local currencies, due in part to inventory stocking for a promotional program aimed at patients who used Botox and Juvederm.

• Latisse: $25M, +34% YoY, +47% QoQ in local currencies due to some inventory stocking. Although 1Q11 was on track with AGN’s forecast of 2011 sales of $100M, Latisse is clearly not ramping up as quickly as I expected when the product was approved in late 2008 (#msg-34424441).

• Only weak product was LapBand: $52M, -16% YoY in local currencies; however, LapBand retained a 73% global market share in the category. (JNJ has the rest.)

• Sales of all AGN products in Latin America increased 32% YoY in dollars, thanks in part to the stronger Brazilian Real.

15% of AGN’s overall sales are in emerging markets; CEO, David Pyott thinks this will go to 25-30% in the next five years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist